Department of Virology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Infectious diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Euro Surveill. 2020 May;25(18). doi: 10.2807/1560-7917.ES.2020.25.18.2000603.
Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be validated. We evaluated SARS-CoV-2 IgG and IgA ELISAs in conjunction with the EUROLabworkstation (Euroimmun, Lübeck, Germany). Overall specificities were 91.9% and 73.0% for IgG and IgA ELISAs, respectively. Of 39 coronavirus disease patients, 13 were IgG and IgA positive and 11 IgA alone at sampling. IgGs and IgAs were respectively detected at a median of 12 and 11 days after symptom onset.
抗体筛查方法来检测严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）需要进行验证。我们评估了 SARS-CoV-2 IgG 和 IgA ELISA 与 EUROLabworkstation（Euroimmun，吕贝克，德国）的联合使用。总体特异性分别为 IgG 和 IgA ELISA 的 91.9%和 73.0%。在 39 名冠状病毒病患者中，13 名患者在采样时 IgG 和 IgA 均为阳性，11 名仅 IgA 阳性。IgG 和 IgA 分别在症状出现后 12 天和 11 天的中位数检测到。
